Scarnose International Limited is an Indian enterprise currently undergoing a fundamental strategic transformation. Following a complete change in ownership and management in **late 2023**, the company is pivoting from its legacy in textile trading toward a high-margin, diversified portfolio spanning **Pharmaceuticals, Life Sciences, Specialty Chemicals, and Sustainable Agriculture**. --- ### **Strategic Reorientation: The Pivot to Life Sciences & Hygiene** Historically a textile and agro-commodity trader, the company is aggressively repositioning itself as a "global leader" in healthcare and hygiene to address declining margins in its legacy business. This shift is formalized through an amendment to the **Memorandum of Association (MOA)** and a pending name change to **Devi Lifecare Limited** (formerly proposed as DDJ Agropharma Impex Limited). **Core Growth Verticals:** * **Pharmaceuticals & APIs:** Manufacturing and trading of **Active Pharmaceutical Ingredients (APIs)**, oncology drugs, beta-lactam antibiotics, cephalosporins, vaccines, and fermentation biotech synthetic products. * **Finished Formulations:** Establishing capabilities across multiple dosage forms, including **solids** (tablets, capsules), **liquids** (IV preparations, ampoules, eye drops), and **semi-solids** (creams, gels). * **Animal Health:** Production of **Animal Food Supplements**, including mineral mixes, vitamins, probiotics, and enzyme-based additives. As of **November 2025**, this has become the primary reportable segment. * **Consumer Healthcare & Hygiene:** Entry into the **Personal Hygiene** market, specifically targeting **Sanitary Napkins** (a sector with a projected **12-14% CAGR**), disinfectants, and baby care products. * **Sustainable Agriculture:** Manufacturing **Organic Fertilizers** and agricultural chemicals, supported by farmer education programs and SKU rationalization. --- ### **Corporate Restructuring & New Management Control** The company’s trajectory changed significantly following a **Share Purchase Agreement (SPA)** dated **November 10, 2023**. * **Change in Control:** New promoters (**Mr. Dev Pandya, Ms. Devi Pandya, and Mr. Jigar Pandya**) acquired a **61.90%** equity stake (**19,50,000 shares**). Full management control was assumed in **July 2024**. * **Relocation:** To optimize operations, the registered office was moved from **Ahmedabad** to **Rajkot, Gujarat**. * **Supply Chain Integration:** The company has secured stable sourcing through related-party transactions with **Dada Organics Ltd** and **Dadaji Lifescience Pvt Ltd**, with transaction limits up to **₹100 Crores** each. --- ### **Financial Performance & Capital Structure** While the company experienced a sharp revenue contraction during the transition period, profitability metrics have begun to show recovery under the new management. **Comparative Financial Summary:** | Metric (₹ in Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **1,227.00** | **1,386.34** | **4,106.93** | | **Profit Before Tax (PBT)** | **25.33** | **1.44** | **5.70** | | **Net Profit (PAT)** | **19.10** | **0.93** | **4.34** | | **Earnings Per Share (₹)** | - | - | **0.15** | **Capital Allocation & Liquidity:** * **Authorized Capital:** Increased from ₹3.50 Crore to **₹5.50 Crore** in December 2024. * **Borrowing Power:** Shareholders approved an increase in borrowing limits up to **₹100.00 Crores** to fund organic and inorganic expansion. * **IPO Fund Utilization:** The **₹6.60 Crores** raised in the June 2022 IPO (at **₹55/share**) has been fully deployed toward debt repayment (**₹289.44 Lakhs**), working capital (**₹253.51 Lakhs**), and general corporate purposes. * **Warrant Cancellation:** A proposed **₹23.52 Crore** preferential issue of convertible warrants at **₹112.00** was withdrawn by the Board in **December 2024**. --- ### **Operational Infrastructure & Asset Management** The company employs an integrated value chain model combining manufacturing, trading, and **Clearing & Forwarding (C&F)** services. * **Asset Oversight:** Maintains rigorous records of **Property, Plant, and Equipment (PPE)** with physical verification conducted every **3 years**. * **Inventory Management:** Regular physical audits are performed; discrepancies are strictly maintained within a **10% aggregate limit** per class. * **Regulatory Framework:** Listed on the **BSE SME Exchange**. The company follows **Accounting Standard (AS-17)** for segment reporting and is currently exempt from compulsory **Ind AS** adoption. --- ### **Risk Profile & Compliance Landscape** The transition phase has introduced several regulatory and market-specific challenges that investors should monitor. **1. Regulatory & Governance Risks:** * **Audit Trail:** As of **March 31, 2025**, the company’s accounting software lacked the mandatory **audit trail (edit log)** feature required by the Companies (Accounts) Rules, 2014. * **Insider Trading:** Previous non-compliance regarding the **Structured Digital Database (SDD)** under SEBI (PIT) Regulations. * **Statutory Dues:** Instances of outstanding **TDS payments** exceeding six months were noted in **August 2025**. * **Share Lock-in:** **6,30,030 shares** held by the new promoters are under lock-in until **June 30, 2025**. **2. Market & Operational Risks:** * **Revenue Volatility:** A **66.24%** revenue decline in FY 2023-24 followed a **57.06%** drop the previous year, largely due to a global slowdown in the cotton industry. * **Competitive Pressure:** Facing intense competition from **Chinese imports**, regional players, and private-label brands. * **Social Barriers:** The hygiene segment faces challenges related to social taboos and misinformation in conservative rural geographies. * **Financial Sensitivities:** Exposure to **Interest Rate Risk** via debt-oriented mutual funds and **Price Risk** through quoted equity instruments (FVTOCI). Notably, the company has **zero foreign currency exposure**. --- ### **Future Outlook: 2025 and Beyond** The company is focused on scaling its international footprint and stabilizing its new business segments. By leveraging its new management's expertise in life sciences and the established distribution networks of its related parties, the company aims to transition from a legacy trader to a high-growth, technology-driven healthcare and agricultural solutions provider. Key milestones for 2025 include the completion of the rebranding to **Devi Lifecare Limited** and the full operationalization of its new pharmaceutical and hygiene product lines.